| DC21224 |
NMT1 inhibitor B13 |
NMT1 inhibitor B13 (LCL4) is a myristoylCoA analog that acts as a small molecule inhibitor of NMT1 with IC50 of 77.6 uM, blocks Src myristoylation and Src localization to the cytoplasmic membrane. |
|
| DC21391 |
NNC 05-2090 hydrochloride
Featured
|
NNC 05-2090 is a potent selective GABA transporter inhibitor of mGAT2 with Ki of 1.4 uM. |
|
| DC22893 |
NNC-0640 |
NNC-0640 (NNC 0640, NNC0640) is a potent, selective glucagon receptor (GCGR) negative allosteric modulator with IC50 of 69.2 nM. |
|
| DC21392 |
NNC-711
Featured
|
NNC-711 is a potent and selective inhibitor of GABA uptake by GAT-1 with IC50 of 0.04 uM. |
|
| DC4204 |
Nocodazole
Featured
|
Nocodazole inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM, respectively. Enhances homology-directed repair (HDR) efficiency 9 to 31% (depending on cell cycle phase) and increases Cas9-mediated gene editing frequencies. |
|
| DC4111 |
Nolatrexed (AG-337)
Featured
|
Nolatrexed (AG-337), inhibits purified recombinant human thymidylate synthase (TS) with a Ki of 11 nM, and displays non-competitive inhibition kinetics. It was further shown to inhibit cell growth in a panel of cell lines of murine and human origin, displ |
|
| DC10549 |
Nomifensine maleate
Featured
|
Nomifensine maleate is a selective inhibitor of dopamine uptake, used in adult attention deficit disorder. |
|
| DC9342 |
Noopept |
Noopept (GVS-111) is a medication promoted and prescribed in Russia and neighbouring countries as a nootropic.
|
|
| DCAPI1558 |
Oxiracetam |
Nootropic agent shown to exhibit learning and memory improvement and cognitive function impairment prevention. Mechanism of action has not been quantified, but current theories suggest a modulation of glutamatergic and cholinergic neurotransmissions with |
|
| DC8848 |
Nosiheptide |
Nosiheptide is a bicyclic thiopeptide antibiotic produced by several species of actinomycetes, notably Streptomyces. |
|
| DC26002 |
TOPK inhibitor-1
Featured
|
Novel PDZ binding kinase (PBK) inhibitor. |
.png)
|
| DC26003 |
(R)-9-(4-(1-(dimethylamino)propan-2-yl)phenyl)-8-hydroxythieno[2,3-c]quinolin-4(5H)-one Hydrochloride
Featured
|
Novel PDZ binding kinase (PBK) inhibitor. |
.png)
|
| DC10453 |
NP-118809
Featured
|
NP-118809 is a N-type calcium channel blocker. |
|
| DC11212 |
NP161 |
NP161 is a potent and selective inhibitor of extracellular TRX (Thioredoxin 1) in vitro with IC50 of 0.54 uM. |
|
| DC22179 |
NPD13668 |
NPD13668 (NPD-13668) is a chemical novel modulator of EZH2-mediated gene silencing, inhibits EZH2/PCR2 activity and decreases H3K27me3 levels. |
|
| DC22180 |
NPD8733
Featured
|
NPD8733 (NPD-8733) is a small-molecule ligand of valosin-containing protein (VCP)/p97, binds to the D1 domain of VCP/p97. |
|
| DC8398 |
NPS-1034
Featured
|
NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively. |
|
| DC21928 |
NPT 200-11
Featured
|
NPT200-11 is an orally bioavailable and brain penetrating alpha-synuclein (ASYN) misfolding and aggregation inhibitor. |
|
| DC21397 |
AI-1 |
Nrf2 acticatior AI-1 is a small-molecule inducer of the antioxidant response element (ARE) that activates and stabilizes Nrf2 by covalently modifying Keap1, activates an ARE-dependent luciferase reporter with an EC50 of 2.7 uM. |
|
| DC21398 |
AI-2 |
Nrf2 acticatior AI-2 is a small-molecule inducer of the antioxidant response element (ARE) that activates and stabilizes Nrf2 by covalently modifying Keap1. |
|
| DC20477 |
Nrf2 activator 16 |
Nrf2 activator 16 is a potent Keap1-Nrf2 and Keap1-p-p62 protein-protein interaction inhibitor with IC50 of 0.91 uM and 1.8 uM respectively. |
|
| DC21399 |
AEM1
Featured
|
NRF2 inhibitor AEM1 is a specific small molecule inhibitor of Nrf2 transcriptional activity in cancer cells, shows no activity against a panel of >100 kinases (including isoforms of PI3K, AKT, and PKC). |
|
| DC20251 |
NRX-103094
Featured
|
NRX-103094 is an enhancer of an E3 ligase-substrate interaction. |
|
| DC20254 |
NRX-103095
Featured
|
NRX-103095 is an enhancer of an E3 ligase-substrate interaction. |
|
| DC20248 |
NRX-1532
Featured
|
NRX-1532 is an enhancer of an E3 ligase-substrate interaction. |
|
| DC20249 |
NRX-1933
Featured
|
NRX-1933 is an enhancer of an E3 ligase-substrate interaction. |
|
| DC20252 |
NRX-252114
Featured
|
NRX-252114 is a potent enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCFβ-TrCP. NRX-252114 enhances the binding of pSer33/S37A β-catenin peptide for β-TrCP with an EC50 of 6.5 nM and a Kd of 0.4 nM. NRX-252114 induces mutant β-catenin degradation. |
|
| DC20253 |
NRX-252262
Featured
|
NRX-252262 is an enhancer of an E3 ligase-substrate interaction. |
|
| DC20250 |
NRX2663
Featured
|
NRX-2663 is an enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCFβ-TrCP. NRX-2663 enhances the binding of β-catenin peptide for β-TrCP with an EC50 of 22.9 µM and a Kd of 54.8 nM[1]. |
|
| DC8783 |
NS 9283
Featured
|
NS 9283 is a positive allosteric modulator of α4β2 receptor; increases the potency of Ach-evoked currents ~60 fold without effecting the maximum efficacy (HEK293-hα4β2 cells). |
|
